IP Library Granted Patent US 10,034,912
Granted Patent B2
US 10,034,912 · App. 15/344,813 · Granted Jul 31, 2018

SMAC Mimetic

Inventors: Stephen M. Condon (Glenmoore, PA); Yijun Deng (Dresher, PA); Matthew G. Laporte (Honeybrook, PA); Susan R. Rippin (Wilmington, DE)
Assignee: TetraLogic Birinapant UK Ltd.
A61K38/05A61K31/555A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,034,912
App. No.
15/344,813
Granted
Jul 31, 2018
Kind
B2
Abstract

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Claims (19)

1. A method of treating cancer in a mammal in need thereof that comprises administering to the mammal an effective amount of Compound 15 of the following formula:

where R5 is —CH 2 CH 3 , or a pharmaceutically acceptable salt thereof, in combination with a second cancer therapy that is chemotherapy.

2. The method of claim 1 wherein the cancer is ovarian cancer.

3. The method of claim 1 wherein the chemotherapy comprises administration of a platinum containing DNA modifying agent.

4. The method of claim 2 wherein the chemotherapy comprises administration of a platinum containing DNA modifying agent.

5. The method of claim 3 wherein the chemotherapy comprises administration of carboplatin, cisplatin, or oxaliplatin.

6. The method of claim 4 wherein the chemotherapy comprises administration of carboplatin, cisplatin, or oxaliplatin.

7. The method of claim 1 wherein the chemotherapy comprises administration of carboplatin.

8. The method of claim 2 wherein the chemotherapy comprises administration of carboplatin.

9. A method for inducing apoptosis in a cancer cell comprising contacting the cell with Compound 15 of the following formula:

where R5 is —CH 2 CH 3 , or a pharmaceutically acceptable salt thereof, and also contacting the cell with a second cancer therapy that is chemotherapy.

10. The method of claim 9 wherein the cancer cell is an ovarian cancer cell.

11. The method of claim 9 wherein the chemotherapy comprises administration of a platinum containing DNA modifying agent.

12. The method of claim 10 wherein the chemotherapy comprises administration of a platinum containing DNA modifying agent.

13. The method of claim 9 wherein the chemotherapy comprises administration of carboplatin, cisplatin, or oxaliplatin.

14. The method of claim 9 wherein the chemotherapy comprises administration of carboplatin.

15. The method of claim 10 wherein the chemotherapy comprises administration of carboplatin.

16. The method of claim 1 wherein Compound 15 is administered by intravenous infusion.

17. The method of claim 1 wherein Compound 15 is administered by intravenous bolus.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 047436 FRAME: 0203. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 25, 2021
From: TETRALOGIC BIRINAPANT UK LTD.
To: MEDIVIR AB
Reel/Frame 056392/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2018
From: TETRALOGIC BIRINAPANT UK
To: MEDIVIR AB
Reel/Frame 047436/0203 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2016
From: TETRALOGIC PHARMACEUTICALS CORPORATION
To: TETRALOGIC BIRINAPANT UK LTD
Reel/Frame 040248/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2016
From: CONDON, STEPHEN M.; DENG, YIJUN; LAPORTE, MATTHEW G.; RIPPIN, SUSAN R.
To: TETRALOGIC PHARMACEUTICALS CORP.
Reel/Frame 040248/0940 →
Continuity (6)
Continuation 14607752 · Jan 28, 2015
Continuation 14075190 · Nov 8, 2013
Continuation 13611274 · Sep 12, 2012
Division 12819221 · Jun 20, 2010
Provisional Application 61222668 · Jul 2, 2009
Related Publication 20170182116A1 · Jun 29, 2017